

**Th17 -**

. . . ;  
 . . . \* , - . . . ,  
 «  
 . . . » , . . . ;  
 \* , . . .  
 - (Th17) -  
 CD4+ - IL-17  
 Th17  
 : Th17-  
 (Th17) -  
 CD4+ - IL-17  
 Th17  
 : Th17-  
 30  
 - 1- 2- (Th1/Th2) [1].  
 [2].  
 (Th0) CD4+ - TCR  
 [3].  
 [3]. (IL)-12 STAT4  
 Th1- , CD4+ - (IFN- ). IL-12 IFN- ,  
 Th1- , STAT4- STAT1-  
 -bet,  
 IFN- ( ) Th1- .

Th1 (TNF- ) IL-10. IFN- ,

Th1- ,

(IgG2a).

STAT6- , IL-4, Th2-  
 CD4+ - GATA3,  
 IL-4, IL-5, IL-13, IL-21 IL-31. Th2-

Th1- Th1- Th1- [4-7]. Th0

Th1/Th2- (T<sub>REG</sub>), CD4 CD25. Th3  
 [8,9]. Th3- IL-2  
 TGF- ( T<sub>REG</sub>). CD4+ - TGF- CD4+ -  
 STAT5, TGF- FoxP3.  
 T<sub>REG</sub>, IL-2 IFN-  
 IL-10, IL-35 TGF- . T<sub>REG</sub> -  
 T<sub>REG</sub> -  
 IL-10 TGF- .

Th17,

Th1- 17-  
 IFN-

Th1- Th17, CD4+ -  
 IL-6, IL-23, IL-1 TGF- [10]. IL-6 IL-23  
 STAT3, ROR t ROR ,  
 IL-17 , IL-17F, IL-21 IL-22. Th17

2'2010 15

[11–15]. Th17- TGF- IL-6 [16–18],

[19]. TGF- (25 / ) Th17- ,

CD4+CD25+ - (2 / ) IL-6 [16–19].

( ) TGF-

CD4+CD25+FoxP3+ , Th17- , IL-17. FoxP3

ROR t, T<sub>REG</sub>- Th17- .

TGF- FoxP3,

CD4+ - ROR t, T<sub>REG</sub> - .

IL-1) IL-17 [19,20]. ROR t, FoxP3 (IL-6, IL-21, IL-23 Th17- ROR t IL-6 IL-21 [20].

IL-23, Th17- .

IL-23 IL-23

IL-23 Th17- [21]. IL-12 40 IL-23 19. IL-23. IL-12 IL-23, IL-12 IL-23, IL-12 IL-12 40

[22–24]. IL-17- TGF- IL-6 IL-17. in vivo IL-10, IL-23 in vivo IL-17. Th17 IL-10. TGF- IL-6 IL-17 , Th17- , IL-23 in vivo [25].

Th17. Th1- Th2- , , IFN- IL-4, IL-17 [26]. (IL-13, IL-25, IL-27) Th17. Th17- Th17 [27,28]. IL-23 Th17 - CD80, CD86, OX40 ICOS [26]. CD+ - . Th2-

T-2- Th17 IL-17 IL-17 [29-30]. IL-6

Th1- [31-33]. Th2- Th17- IL-6,

( Th2- Th17- ) IL-6

(SCF) [34]. Th2- Th17- - I IL-6

13, Th2- Th17- IL-6.

- I

IL-6, [34].

**Th17-**  
Th17 . Th17

, Th17 -

IL-17 TLR- , IL-1 TNF-

, IL-17R ,

[35]. IL-17

IL-17 IL-17F [36].

Th17-

Th17- IL-17, IL-26, IL-21, IL-22, TNF- - [37].

Th2- [37]. Th1-, Th2-

Th17-

[38].

Th17 80% Th17- 4 (

Th1 Th2 20% 60% ).  
 (T<sub>REG</sub>), IL-10 TGF-  
 Th1-  
 Th2-, Th17- Th17-  
 Th1- ( ),  
 IL-17 IL-23, Th17- ,  
 [39]. IL-17 [40].

II  
 IL-15, TNF- IL-18.  
 IL-17 IFN- [39].  
 IL-17 IL-6,  
 [41,42].  
 in vitro IL-17, IL-6 IL-8  
 IL-2, IL-4, IL-13, IL-17 IL-5.  
 Th2/Th17-  
 Th1 -  
 [43].  
 Th17- ( )  
 IL-17 ( )  
 [44, 45]. IL-17 IL-22  
 [46]. Th17-  
 [46]. IL-17  
 ( I -2), ( -1),  
 (G-CSF), IL-6 [47,48].  
 IL-17  
 , IL-1 TNF- [49].  
 IL-17 CD4+IL-17+ CD8+IL-17+,  
 IL-17- [50].  
 IL-17



20–30% of CD4+ T lymphocytes express the (ORF) - Herpesvirus saimiri 63%  
 CTLA-8. IL-17  
 (I -1)  
 G-CSF PGE-2. / Th17 IL-6, IL-8,  
 IL-17 CD34+  
 -3,  
 ( )  
 Th17  
 IFN- (Th1), IL-4, IL-5, IL-13 (Th2) IL-17 (Th17).

## SUMMARY

### THE ROLE OF TH17-CELLS IN THE PATHOGENESIS OF AUTOIMMUNE DISEASES

**P. Dyachenko, . Dyachenko\***

State Establishment "Institute of Epidemiology and Infectious Diseases named after L.V. Gromashevsky of AMS of Ukraine", Kyiv;

\*Sumy State University, Sumy

*A new subtype of CD4+ T lymphocytes have recently been described, and have provided new insights into the mechanism that are important in the development of autoimmune diseases and the immune responses that are essential for effective antimicrobial host defense.*

**Key words:** *Th17 lymphocytes, autoimmune diseases.*

1. Coffman R.L. T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma / R.L. Coffman, J.A. Carty // J. Immunol.-1986.-V.136.-P.949-54.
2. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins / T.R.Mosmann, H.Chervinski, M.W.Bond, M.A.Giedlin, R.L.Caffman // J.Immunol.-1986.-V.136.-P.2348-57.
3. Mosmann T.R. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties / T.R. Mosmann, R.L. Coffman // Annu. Rev. Immunol.-1989.-V.7.-P.145-173.
4. Wilson C.B. Epigenetic control of T-helper-cell differentiation / C.B. Wilson, E. Rowell, M. Sekimata // Nat. Rev. Immunol.-2009.-V.9.-P.91-105.
5. Th1/Th2 cells in inflammatory disease states: therapeutic implications / R.B. Moss, T. Moll, M. El-Kalay, C. Kohne, W. Soo Hoo, J. Encinas et al. // Expert. Opin. Biol. Ther.-2004.-V.4.-P.1887-1896.
6. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage / L.Steinman // Nat.Med.-2007.-V.13.-P.139-145.
7. Monteleone G. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses / G.Monteleone, F.Pallone, T.T.MacDonald // Trends Immunol.-2008.-V.29.-P.290-294.
8. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses / S. Sakaguchi // Annu. Rev. Immunol.-2004.-V.22.-P.531-562.
9. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers / E.M.Shevach // Nat.Rev. Immunol.-2002.-V.2.-P.389-400.

10. Stockinger B. Differentiation and function of Th17 T cells / B. Stockinger, M. Veldhoen // *Curr. Opin. Immunol.*–2007.–V.19.–P.281–286.
11. Vojdani A. Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I) / A. Vojdani, J. Erde // *eCAM* 2006; 3(1) 25–30; doi:10.1093/ecam/nek022.
12. Vojdani A. Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating allergic and infectious disease pathology (II) / A. Vojdani, J. Erde // *eCAM* 2006; 3(2) 209–215.
13. Vojdani A. Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III) // A. Vojdani, J. Erde // *eCAM* 2006; 3(3) 309–316 doi:10.1093/ecam/nel047.
14. Chung Y. Don't leave home without it: the IL–23 visa to TH–17 cells / Y. Chung, C. Dong // *Nature Immunol.* –2009.–V.10.–P.236–238.
15. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo / M.J. McGeachy, Y. Chen, C.M. Tato, A. Laurence, B. Joyce–Shaikh, W.M. Blumenschein et al. // *Nature Immunol.*–2009.–V.10.–P.314–324.
16. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL–17–producing T cells / M. Veldhoen, R.J. Hocking, C.J. Atkins, R.M. Locksley, B. Stockinger // *Immunity.*–2006.–V.24.–P.179–189.
17. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells / E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka et al. // *Nature.*–2006.–V.441.–P.235–238.
18. Transforming growth factor–beta induces development of the T(H)17 lineage / P.R. Mangan, L.E. Harrington, D.B. O'Quinn, W.S. Helms, D.C. Bullard, C.O. Elson et al. // *Nature.*–2006.–V.441.–P.231–234.
19. A critical function for transforming growth factor– , interleukin 23 and proinflammatory cytokines in driving modulating human TH–17 responses / E. Volpe, N. Servant, R. Zollinger, S.I. Bogiatzi, P. Hupe, E. Barillot et al. // *Nat. Immunol.*– 2008.–V.9.–P.650–657.
20. TGF– induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORt function / L. Zhou, J.E. Lopes, M.M.W. Chong, I.I. Ivanov, R. Min, G.D. Victora, et al. // *Nature.*– 2008.–V.453.–P.236–240.
21. Phenotypic and functional features of human TH17 cells / F. Annunziato, L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi et al. // *J.Exp.Med.*– 2007.–V.204.–P.1849–1861.
22. Anti–interleukin–12 antibody for active Crohn's disease / P.J.Mannon, I.J. Fuss, L. Mayer, C.O. Elson, W.J. Sandborn, D. Present et al. // *N. Engl. J. Med.*– 2004.–V.351.–P.2069–2079.
23. Efficacy and safety of ustekinumab, a human interleukin–12/23 monoclonal antibody, in patients with psoriasis: 52–week results from a randomised, double–blind, placebo–controlled trial (PHOENIX 2) / K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding et al. // *Lancet.*– 2008.–V.371.–P. 1675–1684.
24. A phase I trial of an interleukin–12/23 monoclonal antibody in relapsing multiple sclerosis / L.H. Kasper, D. Everitt, T.P. Leist, K.A. Ryan, M.A. Mascelli, K. Johnson et al // *Curr. Med. Res. Opin.*– 2006.–V.22.– P.1671–1678.
25. TGF–beta and IL–6 drive the production of IL–17 and IL–10 by T cells and restrain T(H)–17 cell–mediated pathology / M.J. McGeachy, K.S. Bak–Jensen, Y. Chen, C.M. Tato, W. Blumenschein, T.Mc Clanahan et al. // *Nat.Immunol.*– 2007.–V.8.–P.1390–1397.
26. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 / H. Park, Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang et al. // *Nat.Immunol.*– 2005.–V.6.–P.1133–1141.
27. Suppressive effect of IL–27 on encephalolithogenic TH17 cells and the effector phase of experimental autoimmune encephalomyelitis / D.C. Fitzgerald, B. Ciric, T. Touil, H. Harle, J. Grammatikopolou, S.J. Das et al. // *J. Immunol.*– 2007.–V.179.–P.3268–3275.
28. IL–25 regulates TH17 function in autoimmune inflammation / M.A. Kleinschek, A.M. Owyang, B. Joyce–Shaikh, C.L. Langrish, Y. Chen, D.M. Gorman et al. // *J. Exp. Med.*– 2007.–V.204.–P.161–170.
29. IL–17 cytokine family / M. Kawaguchi, M. Adachi, N. Oda, F. Dodubu, S.K. Huang. // *J. Allergy Clin. Immunol.* – 2004.–V.114.–P.1265–1273.
30. Kolis J.K. Interleukin–17 family members and inflammation / J.K.Kolis, A.Linden// *Immunity.* – 2004.– V. 21.–P.467–476.
31. Interleukin (IL)–6 directs the differentiation of IL–4–producing CD4+ T cells/ Rincon M., Anguita J., Nakamura T., Fikrig E., Flavell RA.// *J. Exp. Med.* – 1997. – 185. – P. 461–9.
32. IL–6 production by pulmonary dendritic cells impedes TH1 immune responses / Dodge I.L., Carr M.W., Cernadas M., Brenner M.B. // *J. Immunol.* – 2003. – 170. –P. 4457–64.
33. Interleukins 1 and 6 but not transforming growth factor– are essential for the differentiation of interleukin 17–producing human T-helper cells / Acosta–Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. // *Nat. Immunol.* – 2007. – 8. –P. 942–9.
34. Vanhaesebroeck B. et al. Activation of C–Kit in dendritic cells regulates T-helper cell differentiation and allergic asthma / Krishnamoorthy N., Oriss T.B., Paglia M., Fei M., Yarlalagadda M. // *Nat. Med.* – 2008. – 14. – P.565–73.
35. Yu J.J. Interleukin–17: a novel inflammatory cytokine that bridges innate and adaptive immunity/ Yu J.J., Gaffen S.L. // *Front Biosci.* – 2008. – 13. – P.170–177.
36. IL–17 family cytokines and the expanding diversity of effector T cell lineages / Weaver C.T., Hatton R.D., Hangan P.R., Harrington L.E. // *Annu. Rev. Immunol.* – 2007. – 25. – P. 821–52.

37. Pene J. Chronically inflamed human tissues are infiltrated by highly differentiated TH17 lymphocytes / Pene J., Chavalier S., Preisser L., Venereau E., Guilleux M.H., Ghannam S. et al. // *J. Immunol.* – 2008. – 18. – P.7423–30.
38. Th1, Th2 and Th17 effector T cell–induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells / Stummvoll G.H., DiPaolo T.S., Glass D., Ward J.M., Shevah E.M. // *J. Immunol.* – 2008. – 181. – P.1908–16.
39. Effector function of type II collagen–stimulated T cells from rheumatoid arthritis patients: cross–talk between T cells and synovial fibroblasts/ Cho M.L., Yoon C.H., Hwang S.Y., Park M.K., Min S.Y., Lee S.H. et al. // *Arthritis Rheum.* – 2004. – 50. – P.776–784.
40. Aarvak T. IL–17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells / Aarvak T., Chabaud M., Miossec P., Natvig J.B. // *J. Immunol.* – 1999. – 162. – P.1246–1251.
41. IL–17 derived from juxta–articular bone and synovium contributes to joint degradation in rheumatoid arthritis / Chabaud M., Lubberts E., Joosten L., van Den Berg W., Miossec P. // *Arthritis Res.* – 2001. – 3. – P.168–177.
42. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro / Van Bezooijen R.L., Van Der Wee–Pals L., Papapoulos S.E., Lowik C.W. // *Ann. Rheum. Dis.* – 2002. – 61. – P.870–876.
43. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin/ Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N. et al. // *Arthritis Res. Ther.* – 2005. – 7. – P.784–795.
44. Therapeutic efficacy of IL–17 neutralization in murine experimental autoimmune encephalomyelitis / Hofstetter H.H., Ibrahim S.M., Koczan D., Druse N., Weishaupt A., Toyka K.V. et al. // *Cell. Immunol.* – 2005. – 237. – P.123–30.
45. Intrathecal activation of the IL–17/IL–8 axis in opticospinal multiple sclerosis / Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y. et al. // *Brain* – 2005. – 128. – P.988–1002.
46. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation / H. Kebir, K. Kreyenborg, I. Ifergan, A. Dodelet–Devillers, R. Cayrol, M. Bernard et al. // *Nat. Med.* – 2007. – V.13. – P.1173–1175.
47. Interleukin–17 family and IL–17 receptors / T.A. Moseley, D.R. Haudenschild, L. Rose, A.H. Reddi // *Cytokine Growth Factor Rev.* – 2003. – V.14. – P.155–174.
48. Kolls J.K. Interleukin–17 family members and inflammation / J.K. Kolls, A. Linden // *Immunity.* – 2004. – V. 21. – P.467–476.
49. IL–17 stimulates the production and expression of proinflammatory cytokines, IL–6 and TNF $\alpha$ , by human macrophages / D.V. Jovanovic, B.J.A. Di, J. Martel–Pelletier, F.C. Johcoeur, Y.He, M. Zhang et al. // *J. Immunol.* – 1998. – V.160. – P.3513–3521.
50. Interleukin–17 production in central nervous system–infiltrating T cells and glial cells is associated with active disease in multiple sclerosis / J.S. Tzartos, M.A. Friese, M.J. Craner, J. Palace, J. Newcombe, M.M. Esiri et al. // *Am. J. Pathol.* – 2008. – V.172. – P.146–155.
51. Production and function of IL–17 in microglia / J. Kawanokuchi, K. Shimizu, A. Nitta, K. Yamada, T. Mizuno, H. Tadeuchi et al. // *J. Neuroimmunol.* – 2008. – V.194. – P.54–61.
52. Metalloproteinases in biology and pathology of the nervous system / V.W.Yong, C.Power, P. Forsyth, D.R. Edwards // *Nat. Rev. Neurosci.* – 2001. – V.2. – P.502–511.
53. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP–8 activity / A.M. Tester, J.H.Cox, A.R. Connor, A.E. Starr, R.A. Dean, X.S. Puente et al. // *PLoS ONE.* – 2007. – 2. – 312p.
54. Proteolytic activation of alternative CCR1 ligands in inflammation / R.D. Berahovich, Z. Miao, Y.Wang, B.Premack, M.C. Howard, T.J. Schall // *J. Immunol.* – 2005. – V.174. – P.7341–7351.
55. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells / I.M. Stromnes, L.M. Cerretti, D. Liggitt, R.A. Harris, J.M. Goverman // *Nat. Med.* – 2008. – V.14. – P.337–342.
56. Human CD25<sup>high</sup>Foxp3<sup>pos</sup> regulatory T cells differentiate into IL–17–producing cells / H.J. Koenen, R.L. Smeets, P.M. Vink, E. van Rijssen, A.M. Boots, I. Joosten // *Blood.* – 2008. – V.112. – P.2340–2352.
57. Manel N. The differentiation of human T(H)–17 cells requires transforming growth factor–beta and induction of the nuclear receptor ROR $\gamma$  / N. Manel, D. Unutmaz, D.R. Littman // *Nat. Immunol.* – 2008. – V.9. – P. 641–649.